Impacto de la suplementación con micronutrientes antes del embarazo en los resultados maternos e infantiles
The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Low birth weight and anemia remain intractable problems in many developing countries despite considerable efforts to address them. Intervening with just prenatal iron-folate (IFA) supplements may not be the best approach given the substantial demands for iron by maternal and fetal tissues. Therefore, there is an urgent need to evaluate the additional contribution of prepregnancy interventions.
Low birth weight (LBW) and anemia remain public health problems in many developing countries. There is a great deal of evidence in the literature that anemia, primarily due to iron deficiency, has been associated with poor birth outcomes and LBW. The most common interventions is the provision of iron-folate (IFA) supplements during pregnancy. Despite several decades of effort, the success of these interventions in improving anemia and LBW was limited due to: inadequate coverage, high costs and an inability to sustain the programs. Reasons for low effectiveness also include inadequacy of delivery systems, side effects and poor compliance among pregnant women. In addition, intervening with iron-folate (IFA) supplements during pregnancy alone may not be sufficient as many women enter pregnancy with suboptimal iron stores. Weekly pre-pregnancy IFA supplementation (WIFS) has been introduced as a way to reduce the burden of anemia and improve birth outcomes. WIFS has been shown to improve iron status and reduce the burden of anemia in Women of Reproductive Age (WRA) in the short term, but no study has assessed the effects of this intervention on birth outcomes.
The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status. The study will be conducted in Vietnam, a developing country, where anemia and Iron Deficiency (ID) are highly prevalent and will provide valuable scientific evidence that will inform policy. Infants born to women receiving the intervention are followed up to age 10 to 11 to assess periconception nutrition on early adolescent body size, anemic status, cognitive and academic achievement.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Thái Nguyên
-
Thai Nguyen, Thái Nguyên, Vietnam, 24000
- Thai Nguyen University of Medicine and Pharmacy
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria for Women:
- 18-35 years old
- Currently married
- Currently living in one of the 10 communes and intends to live in the areas for 24 months following recruitment
- Plans to have children in the next year
- Agrees to participate with informed consent
Exclusion Criteria for Women:
- Currently pregnant
- Delivered in the previous six months
- Regularly consumed IFA or MM supplements in the past 2 months
- Severe anemia (Hb < 7 g/L)
- History of high risk pregnancy including abruptio placenta, placenta previa, gestational diabetes, pregnancy induced hypertension, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use
- Chronic hematological diseases, hereditary defects of red cells or hemoglobin
Inclusion Criteria for Offspring:
- Child of a female participant of the original study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Multiple Micronutrient - 1
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy. |
There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:
|
|
Comparador activo: Iron and Folic Acid - 1
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current World Health Organization (WHO) recommendations for WRA. |
The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA. |
|
Comparador de placebos: Folic Acid - 1
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period. |
It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA. |
|
Experimental: Multiple Micronutrient - 2
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive a supplement that is taken weekly during pre-pregnancy. |
There is no current recommendation for weekly MM supplements for WRA. Therefore, the researchers propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/United Nations University (UNU) recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy and contains:
|
|
Comparador activo: Iron and Folic Acid - 2
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA. |
The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA. |
|
Comparador de placebos: Folic Acid - 2
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period. |
It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Birth Size - Weight
Periodo de tiempo: At birth
|
Infant weight is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Weight is measured in grams (g). |
At birth
|
|
Birth Size - Body Length
Periodo de tiempo: At birth
|
Infant length is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Length is measured in millimeters (mm). |
At birth
|
|
Birth Size - Head Circumference
Periodo de tiempo: At birth
|
Infant head circumference is measured as early as possible within 24 hours after birth using standard procedures. All measurements are obtained in duplicate by the same data collector. Head circumference is measured in millimeters (mm). |
At birth
|
|
Gestational Age
Periodo de tiempo: At birth
|
Gestational age is calculated based on the date of last menstrual period. This method has been shown to be reliable in previous work and the researchers expect precise estimates since women will be visited weekly from baseline during the pre-pregnancy period. Women who have delivered babies in the past 6 months are excluded. |
At birth
|
|
Child length
Periodo de tiempo: From Birth to 24 months
|
Child length, measured in millimeters (mm) is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age. |
From Birth to 24 months
|
|
Child weight
Periodo de tiempo: From birth through 24 months of age
|
Child weight, measured in grams (g), is measured at birth, 1, 3, 6, 9, 12, 15, 18, and 24 months of age. |
From birth through 24 months of age
|
|
Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III) Score
Periodo de tiempo: 12 and 24 months
|
Child development is measured using the Bayley Scales of Infant and Toddler Development - Third Edition at 12 and 24 months of age. The Bayley-III is a standardized comprehensive assessment tool for assessing child development in children one month to 42 months old. The highest possible scaled score on each subtest is 19, and the lowest possible score is 1. Scores from 8 to 12 are considered average. Index scores for motor and language domains are derived from sums of the subtest scaled scores. Index scores range from 40-160 with higher scores indicating. Composite scores are calculated for the cognitive, language, and motor scales to compare children to a normative age-matched sample. Composite scores have a mean of 100 with a standard deviation of 15. Composite scores below 85 indicate mild cognitive impairment and scores below 70 indicate moderate to severe cognitive impairment. |
12 and 24 months
|
|
Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) Score
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age
|
Child development is measured using the WISC-IV. This test has been validated and adapted in the Vietnamese context and takes 60-70 minutes to administer. The WISC-IV consists of 10 subtests (Vocabulary, Similarities, Comprehension, Block Design, Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and Symbol search). These are summed into four indices: the Verbal Comprehension Index (VCI, a measure of crystallized abilities), Perceptual Reasoning Index (PRI, a measure of inductive and quantitative reasoning), Working Memory Index (WMI, a measure of children's ability to memorize new information), Processing Speed Index (PSI, a measure of the speed of information processing including the ability to focus attention and quickly scan, discriminate and sequentially order visual information). The Full-Scale intelligence quotient (IQ) score ranges from 40 to 160 points with higher scores indicating higher intelligence. Scores of 90 to 109 are considered average. |
6 to 7 years of age, 10 to 11 years of age
|
|
Weight-for-age Z score (WAZ)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age
|
The weight-for-age Z score (WAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements. |
6 to 7 years of age, 10 to 11 years of age
|
|
Height-for-Age Z Score (HAZ)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age
|
The height-for-age Z score (HAZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements. |
6 to 7 years of age, 10 to 11 years of age
|
|
Weight-for-Height Z Score (WHZ)
Periodo de tiempo: 6 to 7 years of age
|
The weight-for-height Z score (WHZ) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements. |
6 to 7 years of age
|
|
Body Mass Index Z Score (BMI-Z)
Periodo de tiempo: 10 to 11 years of age
|
The body mass index Z Score (BMI-Z) is assessed in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements. |
10 to 11 years of age
|
|
Body composition (Lean mass/fat free mass index)
Periodo de tiempo: 6 to 7 years of age, 10 to 11 years of age
|
Body composition (Lean mass/fat free mass index) in offspring of women receiving only FA, offspring of women who receive weekly pre-pregnancy IFA, and offspring of women who receive weekly MM supplements |
6 to 7 years of age, 10 to 11 years of age
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mothers' iron status
Periodo de tiempo: At baseline, 1 month postpartum, 3 months postpartum
|
Venous blood samples (5 ml) will be collected from women at: baseline, the first prenatal visit and at 1 and 3 months post partum. Anemia will be defined as Hb value <12 g/L for non-pregnant women, and <11g/L for pregnant women and infants, and iron deficiency as serum ferritin <12 μg/L (93). |
At baseline, 1 month postpartum, 3 months postpartum
|
|
Infants' iron status
Periodo de tiempo: Birth, 3 months of age
|
Infant iron status is measured in cord blood samples (5 ml) obtained at delivery and at 3 months of age using a capillary blood sample that is obtained from a heel prick. The hemoglobin concentration are measured from a drop of blood using the HEMOCUE B- Hb photometer. The blood samples are then centrifuged and serum samples are aliquoted into microcuvettes and handled in the same way as described for mothers. Serum ferritin and transferrin receptor concentrations will be assayed using the ELISA method. |
Birth, 3 months of age
|
|
Center for Epidemiological Studies Depression Scale (CES-D) Score
Periodo de tiempo: At baseline, during pregnancy, 3 months postpartum
|
Maternal depression is assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report instrument asking respondents if they have experienced symptoms of depression during the past week. Responses are given on a scale of 0 to 3 where rarely is scored as 0 and most of the time is scored as 3. Total scores range from 0 to 60 and higher scores indicate greater symptoms of depression. |
At baseline, during pregnancy, 3 months postpartum
|
|
Edinburgh Postnatal Depression Scale (EPDS) Score
Periodo de tiempo: At baseline, during pregnancy, 3 months postpartum
|
Maternal depression is assessed with the Edinburgh Postnatal Depression Scale (EPDS). The EPDS includes 10-items asking participants about symptoms of depression that they have experienced in the past 7 days. Responses are given on a 4-point scale where 0 corresponds with the least amount of symptoms and 3 corresponds with the highest amount of symptoms. Total scores range from 0 to 30 with higher scores indicating increased symptoms of depression. Scores of 10 and greater indicate possible depression. |
At baseline, during pregnancy, 3 months postpartum
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Academic Achievement
Periodo de tiempo: 10 to 11 years of age
|
Academic achievement is evaluated with an assessment tool that has been used previously in Vietnam as part of the Young Lives Study. Study participants will take assessments in mathematics and Vietnamese (reading) at the beginning of the academic year when they enter Grade 5 in the school setting. Each test will take approximately 45 minutes. The test instruments in both math and reading employ a 30-item multiple-choice format and were developed in consultation with curriculum experts from the Vietnamese National Institute of Educational Sciences and are in line with those employed in the Ministry of Education & Training (MOET)/World Bank Grade 5 Study to measure learning levels in relation to curricular expectations, covering key subject domains at a range of levels of cognitive demand. |
10 to 11 years of age
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Usha Ramakrishnan, PhD, Emory University
Publicaciones y enlaces útiles
Publicaciones Generales
- Nguyen PH, Lowe AE, Martorell R, Nguyen H, Pham H, Nguyen S, Harding KB, Neufeld LM, Reinhart GA, Ramakrishnan U. Rationale, design, methodology and sample characteristics for the Vietnam pre-conceptual micronutrient supplementation trial (PRECONCEPT): a randomized controlled study. BMC Public Health. 2012 Oct 24;12:898. doi: 10.1186/1471-2458-12-898.
- Nguyen PH, DiGirolamo AM, Gonzalez-Casanova I, Pham H, Hao W, Nguyen H, Truong TV, Nguyen S, Harding KB, Reinhart GA, Martorell R, Ramakrishnan U. Impact of preconceptional micronutrient supplementation on maternal mental health during pregnancy and postpartum: results from a randomized controlled trial in Vietnam. BMC Womens Health. 2017 Jun 17;17(1):44. doi: 10.1186/s12905-017-0401-3.
- Nguyen PH, Young M, Gonzalez-Casanova I, Pham HQ, Nguyen H, Truong TV, Nguyen SV, Harding KB, Reinhart GA, Martorell R, Ramakrishnan U. Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam. PLoS One. 2016 Dec 5;11(12):e0167416. doi: 10.1371/journal.pone.0167416. eCollection 2016.
- Ramakrishnan U, Nguyen PH, Gonzalez-Casanova I, Pham H, Hao W, Nguyen H, Truong TV, Nguyen S, Harding KB, Reinhart GA, Neufeld LM, Martorell R. Neither Preconceptional Weekly Multiple Micronutrient nor Iron-Folic Acid Supplements Affect Birth Size and Gestational Age Compared with a Folic Acid Supplement Alone in Rural Vietnamese Women: A Randomized Controlled Trial. J Nutr. 2016 Jul;146(7):1445S-52S. doi: 10.3945/jn.115.223420. Epub 2016 Jun 8.
- Nguyen PH, Gonzalez-Casanova I, Young MF, Truong TV, Hoang H, Nguyen H, Nguyen S, DiGirolamo AM, Martorell R, Ramakrishnan U. Preconception Micronutrient Supplementation with Iron and Folic Acid Compared with Folic Acid Alone Affects Linear Growth and Fine Motor Development at 2 Years of Age: A Randomized Controlled Trial in Vietnam. J Nutr. 2017 Aug;147(8):1593-1601. doi: 10.3945/jn.117.250597. Epub 2017 Jun 14.
- Nguyen PT, Nguyen PH, Tran LM, Khuong LQ, Van Nguyen S, Young MF, DiGirolamo A, Ramakrishnan U. The Relationship of Preterm and Small for Gestational Age with Child Cognition During School-Age Years. J Nutr. 2024 Aug;154(8):2590-2598. doi: 10.1016/j.tjnut.2024.06.012. Epub 2024 Jun 25.
- Ramakrishnan U, Wimalasena ST, Young MF, Khuong LQ, Tran LM, Hoffman DJ, Martorell R, Nguyen PH. Preconception Micronutrient Supplementation Affects Maternal BMI and Body Composition Postpartum: A Randomized Controlled Trial in Vietnam. J Nutr. 2024 Apr;154(4):1440-1448. doi: 10.1016/j.tjnut.2024.02.024. Epub 2024 Feb 26.
- Duong C, Young MF, Nguyen PH, Tran L, Patel S, Ramakrishnan U. Temporal Dietary Diversity Patterns Are Associated with Linear Growth but Not Ponderal Growth in Young Children in Rural Vietnam. J Nutr. 2023 Oct;153(10):3083-3091. doi: 10.1016/j.tjnut.2023.06.030. Epub 2023 Jun 25.
- Young MF, Nguyen PH, Addo OY, Hao W, Nguyen H, Pham H, Martorell R, Ramakrishnan U. The relative influence of maternal nutritional status before and during pregnancy on birth outcomes in Vietnam. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:223-7. doi: 10.1016/j.ejogrb.2015.09.018. Epub 2015 Sep 28.
- Nguyen PH, Tran LM, Khuong LQ, Nguyen PT, Van Nguyen B, Be TH, Young MF, DiGirolamo AM, Martorell R, Ramakrishnan U. Preconception micronutrient supplementation positively affects offspring perceptual reasoning at 10-11 years of age: follow-up of a randomized controlled trial in Vietnam. Am J Clin Nutr. 2026 May;123(5):101270. doi: 10.1016/j.ajcnut.2026.101270. Epub 2026 Mar 12.
- Young MF, Nguyen PH, Tran LM, Khuong LQ, Hendrix S, Martorell R, Ramakrishnan U. Maternal preconception BMI and gestational weight gain are associated with weight retention and maternal and child body fat at 6-7 years postpartum in the PRECONCEPT cohort. Front Nutr. 2023 May 26;10:1114815. doi: 10.3389/fnut.2023.1114815. eCollection 2023.
- Gonzalez-Casanova I, Nguyen PH, Young MF, Harding KB, Reinhart G, Nguyen H, Nechitillo M, Truong TV, Pham H, Nguyen S, Neufeld LM, Martorell R, Ramakrishnan U. Predictors of adherence to micronutrient supplementation before and during pregnancy in Vietnam. BMC Public Health. 2017 May 16;17(1):452. doi: 10.1186/s12889-017-4379-4.
- Young MF, Hong Nguyen P, Addo OY, Pham H, Nguyen S, Martorell R, Ramakrishnan U. Timing of Gestational Weight Gain on Fetal Growth and Infant Size at Birth in Vietnam. PLoS One. 2017 Jan 23;12(1):e0170192. doi: 10.1371/journal.pone.0170192. eCollection 2017.
- Nguyen PH, Young MF, Khuong LQ, Tran LM, Duong TH, Nguyen HC, Martorell R, Ramakrishnan U. Maternal Preconception Body Size and Early Childhood Growth during Prenatal and Postnatal Periods Are Positively Associated with Child-Attained Body Size at Age 6-7 Years: Results from a Follow-up of the PRECONCEPT Trial. J Nutr. 2021 May 11;151(5):1302-1310. doi: 10.1093/jn/nxab004.
- Young MF, Nguyen P, Tran LM, Khuong LQ, Martorell R, Ramakrishnan U. Long-Term Association Between Maternal Preconception Hemoglobin Concentration, Anemia, and Child Health and Development in Vietnam. J Nutr. 2023 May;153(5):1597-1606. doi: 10.1016/j.tjnut.2023.03.015. Epub 2023 Mar 15.
- Deputy NP, Nguyen PH, Pham H, Nguyen S, Neufeld L, Martorell R, Ramakrishnan U. Validity of gestational age estimates by last menstrual period and neonatal examination compared to ultrasound in Vietnam. BMC Pregnancy Childbirth. 2017 Jan 11;17(1):25. doi: 10.1186/s12884-016-1192-5.
- Tran LM, Nguyen PH, Young MF, Ramakrishnan U, Alderman H. Home environment and nutritional status mitigate the wealth gap in child development: a longitudinal study in Vietnam. BMC Public Health. 2023 Feb 8;23(1):286. doi: 10.1186/s12889-023-15156-2.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Procesos Patológicos
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades metabólicas
- Trabajo de parto prematuro, obstétrico
- Complicaciones obstétricas del parto
- Complicaciones del embarazo
- Enfermedades Fetales
- Trastornos del crecimiento
- Enfermedades hematológicas
- Trastornos del metabolismo del hierro
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Nutricionales y Metabólicas
- Enfermedades hemic y linfáticas
- Deficiencias de hierro
- Nacimiento prematuro
- Retraso del crecimiento fetal
- Anemia
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Químicos inorgánicos
- Elementos
- Rieles
- Pterins
- Pteridinas
- Metales, pesado
- Elementos de transición
- Ácido fólico
- Hierro
Otros números de identificación del estudio
Otros números de identificación del estudio
- IRB00051384
- 10-1196-UEMORY-01 (Otro identificador: Other)
- 2025P009844 (Otro identificador: Emory IRB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .